BioCentury | Jun 19, 2019
Distillery Therapeutics

Inhibiting miR-181a and miR-181b could treat obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Inhibition of miR-181a and miR-181b or treatment with indole -- a negative regulator of the two microRNAs -- could help treat obesity. Expression of miR-181a2 and miR-181b2 in white adipose...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and mouse studies suggest inhibiting miR-181a or NFAT5 could help treat islet autoimmunity, a precursor to Type I diabetes. In blood samples from children of Type I diabetes patients, T cell...
BioCentury | Apr 28, 2016

Public-Private Partnership Roundup

Public-private partnerships (PPPs) continue to accumulate at a high rate in the preclinical space, with 56 deals disclosed in 1Q16, but the data suggest the nature of the deals is moving away from large disease-centric...
BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

...Notch 1 (NOTCH1); microRNA-181a (miR-181a); miR-181b-1 Mouse and cell culture studies suggest inhibiting miR-181a and miR-181b-1... treat NOTCH1 pathway-driven T cell ALL. In mouse models of the disease, miR-181a and miR-181b-1...
...with normal expression of both. Next steps could include evaluating pharmacological inhibitors of miR-181a and miR-181b-1...
BioCentury | Jun 7, 2012
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation MicroRNA-181b (miR-181b) Patient sample and mouse studies suggest agonizing miR-181b could help treat inflammation. In a mouse model of endotoxic...
BioCentury | Nov 10, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer MicroRNA-222 (miR-222); miR-181b Studies in mice suggest inhibiting miR-222 or miR-181b could help treat tamoxifen-resistant breast cancer. In tamoxifen-treated xenograft mice with drug-resistant...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) MicroRNA-137 (miR-137); miR-181c; serine palmitoyltransferase long chain base subunit 1 (SPTLC1; LBC1); b-amyloid (Ab) Patient sample and mouse studies suggest miR-137 or...
BioCentury | Sep 9, 2010
Distillery Therapeutics

Indication: Cancer

...information Cancer Colorectal cancer MicroRNA-21 (miR-21); miR-181b-1 Studies in mice suggest that inhibiting miR-21 and miR-181b-1...
...RNAs targeting either miR-21 or miR-181b-1. Next steps could include testing inhibitors of miR-21 and miR-181b-1...
BioCentury | May 6, 2010
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens MicroRNA-based scoring system to predict outcomes in patients with chronic lymphoblastic leukemia (CLL) An miRNA-based scoring system could help predict outcomes in CLL patients....
BioCentury | May 12, 2008
Company News

Regulus Therapeutics LLC, Stanford University deal

Regulus received exclusive rights from Stanford to worldwide patent applications covering methods and compositions for antagonizing microRNA-181a (miRNA-181a) to regulate immune responses. The company plans to develop RNA-based treatments for inflammatory diseases based on the...
Items per page:
1 - 10 of 12